Rezera Inc. filed Amendment No. 1 to its Form S-1 registration statement with the SEC on November 5, 2026, covering an initial public offering of 16,666,667 shares of common stock at an expected price range of $11.00 to $13.00 per share.

Key Highlights

  • Shares offered: Rezera Inc. is offering 16,666,667 shares of common stock in its initial public offering.
  • Price range: The company expects the initial public offering price to be between $11.00 and $13.00 per share.
  • Proposed listing: Rezera has applied to list its common stock on the Nasdaq Global Market under the symbol "RZRA."
  • GSK interest: Glaxo Group Limited, an entity affiliated with GSK plc, has indicated an interest in purchasing up to 2,083,333 shares, representing up to approximately $25.0 million at the $12.00 midpoint, or approximately 10% of common stock outstanding immediately following closing.
  • Underwriter option: Rezera has granted the underwriters a 30-day option to purchase up to 2,500,000 additional shares of common stock.
  • GSK agreement: In November 2026, Rezera entered into a right of first negotiation and clinical advisory board agreement with GSK.
  • Company classification: Rezera is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company under U.S. federal securities laws.

Rezera Inc. IPO Terms, GSK Relationship, and Offering Structure

Rezera Inc., a Delaware-incorporated company with its principal offices at 265 Franklin Street, Suite 1702, Boston, MA, filed Amendment No. 1 to its Form S-1 registration statement (Registration No. 333-299571) on November 5, 2026. According to the filing, Rezera is offering 16,666,667 shares of common stock in what the company describes as its initial public offering, with no prior public market for its shares. The expected price range is $11.00 to $13.00 per share, with a midpoint of $12.00.

The filing discloses that Glaxo Group Limited, affiliated with GSK plc, has indicated an interest in purchasing up to 2,083,333 shares at the initial public offering price, representing up to an aggregate of $25.0 million based on the $12.00 midpoint, or approximately 10% of common stock outstanding immediately following closing. The filing notes that "indications of interest are not binding agreements or commitments to purchase," and GSK may ultimately purchase more, fewer, or no shares. The filing also states that in November 2026, Rezera entered into a right of first negotiation and clinical advisory board agreement with GSK.

Rezera has granted the underwriters a 30-day option to purchase up to 2,500,000 additional shares. Joint bookrunners for the offering are listed as Jefferies, TD Cowen, and Cantor, with Wedbush PacGrow acting as lead manager. The company's President and Chief Executive Officer is identified as Geoffrey McDonough, M.D. Rezera holds SIC code 2834 and an IRS Employer Identification Number of 87-4018930. The filing carries the standard cautionary language that the information in the preliminary prospectus is not complete and may be changed, and that securities may not be sold until the registration statement is effective.

What Was Disclosed

Rezera Inc. filed an amended S-1 registration statement on November 5, 2026, disclosing plans for an IPO of 16,666,667 shares at $11.00 to $13.00 per share, an application to list on the Nasdaq Global Market under "RZRA," GSK's indicated interest in up to $25.0 million of shares, and a November 2026 agreement with GSK.